Oracle's stock surges on cloud growth outlook despite earnings miss, as its $455 billion backlog and ambitious AI-driven expansion plans captivate investors.
Trump administration cracks down on misleading drug ads, issuing cease-and-desist letters to enforce regulations and protect patients.
Inditex reports weaker second-quarter sales amid consumer caution, but signals potential recovery with solid first-half performance and flexible supply chain.
Oracle's stock surges on cloud growth outlook despite earnings miss, as its $455 billion backlog and ambitious AI-driven expansion plans captivate investors.
Trump administration cracks down on misleading drug ads, issuing cease-and-desist letters to enforce regulations and protect patients.
Inditex reports weaker second-quarter sales amid consumer caution, but signals potential recovery with solid first-half performance and flexible supply chain.